SG11202106628YA - Norovirus vaccine formulations and methods - Google Patents
Norovirus vaccine formulations and methodsInfo
- Publication number
- SG11202106628YA SG11202106628YA SG11202106628YA SG11202106628YA SG11202106628YA SG 11202106628Y A SG11202106628Y A SG 11202106628YA SG 11202106628Y A SG11202106628Y A SG 11202106628YA SG 11202106628Y A SG11202106628Y A SG 11202106628YA SG 11202106628Y A SG11202106628Y A SG 11202106628YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- vaccine formulations
- norovirus vaccine
- norovirus
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782733P | 2018-12-20 | 2018-12-20 | |
| PCT/US2019/067961 WO2020132510A1 (en) | 2018-12-20 | 2019-12-20 | Norovirus vaccine formulations and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106628YA true SG11202106628YA (en) | 2021-07-29 |
Family
ID=71101884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106628YA SG11202106628YA (en) | 2018-12-20 | 2019-12-20 | Norovirus vaccine formulations and methods |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220054621A1 (enExample) |
| EP (1) | EP3897712A4 (enExample) |
| JP (1) | JP2022514759A (enExample) |
| KR (1) | KR20210114941A (enExample) |
| CN (1) | CN113453711A (enExample) |
| AR (1) | AR117462A1 (enExample) |
| AU (1) | AU2019404430A1 (enExample) |
| BR (1) | BR112021012181A2 (enExample) |
| CA (1) | CA3123860A1 (enExample) |
| CO (1) | CO2021009379A2 (enExample) |
| IL (1) | IL284233A (enExample) |
| MX (1) | MX2021007502A (enExample) |
| SG (1) | SG11202106628YA (enExample) |
| WO (1) | WO2020132510A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201601660YA (en) | 2007-09-18 | 2016-04-28 | Takeda Vaccines Inc | Method of conferring a protective immune response to norovirus |
| EP3299030B1 (en) | 2011-07-11 | 2022-06-08 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
| EP4340874A1 (en) | 2021-05-21 | 2024-03-27 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
| JPWO2024202045A1 (enExample) * | 2023-03-31 | 2024-10-03 | ||
| WO2025076792A1 (en) * | 2023-10-12 | 2025-04-17 | Chengdu Kanghua Biological Product Co., Ltd. | Methods of preparing norovirus vaccine with low amounts of adjuvant |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006335256B2 (en) * | 2005-11-22 | 2012-10-18 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| SG10201601660YA (en) * | 2007-09-18 | 2016-04-28 | Takeda Vaccines Inc | Method of conferring a protective immune response to norovirus |
| KR101793161B1 (ko) * | 2008-08-08 | 2017-11-03 | 다케다 백신즈 인코포레이티드 | 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들 |
| US20110070260A1 (en) * | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
| CA2787666A1 (en) * | 2010-01-21 | 2011-07-28 | Ligocyte Pharmaceuticals, Inc. | Targeted heterologous antigen presentation on calicivirus virus-like particles |
| EP3299030B1 (en) * | 2011-07-11 | 2022-06-08 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
-
2019
- 2019-12-19 AR ARP190103785A patent/AR117462A1/es not_active Application Discontinuation
- 2019-12-20 CA CA3123860A patent/CA3123860A1/en active Pending
- 2019-12-20 CN CN201980092246.7A patent/CN113453711A/zh active Pending
- 2019-12-20 BR BR112021012181-1A patent/BR112021012181A2/pt unknown
- 2019-12-20 MX MX2021007502A patent/MX2021007502A/es unknown
- 2019-12-20 KR KR1020217020497A patent/KR20210114941A/ko not_active Withdrawn
- 2019-12-20 SG SG11202106628YA patent/SG11202106628YA/en unknown
- 2019-12-20 WO PCT/US2019/067961 patent/WO2020132510A1/en not_active Ceased
- 2019-12-20 JP JP2021535827A patent/JP2022514759A/ja active Pending
- 2019-12-20 US US17/416,810 patent/US20220054621A1/en active Pending
- 2019-12-20 AU AU2019404430A patent/AU2019404430A1/en active Pending
- 2019-12-20 EP EP19901048.9A patent/EP3897712A4/en active Pending
-
2021
- 2021-06-20 IL IL284233A patent/IL284233A/en unknown
- 2021-07-19 CO CONC2021/0009379A patent/CO2021009379A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220054621A1 (en) | 2022-02-24 |
| EP3897712A1 (en) | 2021-10-27 |
| EP3897712A4 (en) | 2022-08-31 |
| AU2019404430A1 (en) | 2021-07-08 |
| CN113453711A (zh) | 2021-09-28 |
| KR20210114941A (ko) | 2021-09-24 |
| BR112021012181A2 (pt) | 2021-08-31 |
| AR117462A1 (es) | 2021-08-04 |
| CA3123860A1 (en) | 2020-06-25 |
| WO2020132510A1 (en) | 2020-06-25 |
| IL284233A (en) | 2021-08-31 |
| JP2022514759A (ja) | 2022-02-15 |
| MX2021007502A (es) | 2021-10-13 |
| CO2021009379A2 (es) | 2021-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273541A (en) | formulations | |
| ZA202003999B (en) | System and methods | |
| ZA201805805B (en) | Formulations and methods | |
| IL265590B (en) | Formulations and methods for keratin treatment | |
| IL273282A (en) | Niraprib formulations | |
| IL269630A (en) | Niraprib formulations | |
| IL269621A (en) | Niraparib formulations | |
| HRP20251619T1 (hr) | Formulacije pneumokoknih konjugiranih cjepiva | |
| IL275208A (en) | Hsp90-targeting conjugates and formulations thereof | |
| IL284233A (en) | Norovirus vaccine: formulations and methods | |
| IL261347A (en) | Formulations and printing methods | |
| GB201707342D0 (en) | Imaging agents and methods | |
| IL268583A (en) | Preparations and methods for use on the skin | |
| GB201801566D0 (en) | Methods and compositions for nanormulsion vaccine formulations | |
| GB201707367D0 (en) | Vaccine compostions | |
| GB201910794D0 (en) | Vaccine | |
| HUE053871T2 (hu) | Fogászati implantátum és fogászati implantátumrendszer | |
| GB201811382D0 (en) | Vaccine | |
| GB201818904D0 (en) | New formulations and methods | |
| HK40065277A (en) | Norovirus vaccine formulations and methods | |
| SG11202011823SA (en) | Activator-nucleator formulations | |
| GB201807303D0 (en) | Glyconjugate vaccines | |
| GB201819028D0 (en) | Butanol-based formulations | |
| GB201808386D0 (en) | Formulations | |
| GB201804545D0 (en) | Formulations |